Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

ngs derived from Anadys' completed strategic restructuring.

Operating expenses were $9.7 million for the third quarter of 2008, compared to $10.0 million for the third quarter of 2007. Included as a component of Anadys' operating expenses were non-cash, share-based expenses of $0.7 million and $1.4 million for the third quarter of 2008 and 2007, respectively.

The net loss was $9.3 million for the third quarter of 2008, compared to net income of $12.3 million for the third quarter of 2007. Basic and diluted net loss per common share was $0.32 in the third quarter of 2008, compared to net income per common share of $0.43 in the third quarter of 2007. Non-cash share-based expense resulted in a $0.03 increase in basic and diluted net loss per share for the third quarter of 2008 compared to a $0.05 decrease in basic and diluted net income per share for the third quarter 2007.

During the nine months ended September 30, 2008 the Company had no revenue, compared to $23.9 million for the same period in 2007. The revenue recognized in the first nine months of 2007 was primarily derived from the amortization of an upfront payment and a milestone payment under a prior collaboration and the recognition of the previously deferred revenue upon termination of the collaboration. Operating expenses during the nine months ended September 30, 2008 were $25.2 million compared to $28.1 million for the nine months ended September 30, 2007. The decrease in operating expenses was a result of cost savings derived from Anadys' completed restructuring partially offset by increases in development costs for ANA598 and ANA773. For the nine months ended September 30, 2008, Anadys reported a net loss of $23.9 million, compared to $1.4 million for the same period last year. Basic and diluted net loss per common share was $0.83 for the nine months ended September 30, 2008, compared to $0.05 for the same period in 2007.

Recent Development Program Highlights

-- Phase
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 years of ... restoring hope an quality of life and contributing to ... of the innovative cellular biomedicines research that made Topricin® ... , The company was founded in 1994 in a ... of research, and Topricin inventor), Aurora Paradise (COO) and ...
(Date:9/22/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:9/22/2014)... (Nasdaq: NEOG ) announced today that net ... year, which ended Aug. 31, was $8,883,000 — a ... the first quarter of last year. Adjusted for a ... share in the current quarter were $0.24, compared to ... increased 15% to $67,599,000, from the previous year,s first ...
(Date:9/22/2014)... September 22, 2014 The US ... mixed note as the Dow Jones Industrial Average finished ... at 4,579.79, down 0.30%. The S&P 500 finished the ... six out of ten sectors finished on a positive ... the day at 751.48, up 0.10%, with the index ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... following Webcast:, What: Transgenomic Inc. Fourth Quarter ... Conference Call, When: Thursday, February 28, 2008 ... How: Live over the Internet -- Simply log ... address above., To access the call via telephone, call ...
... 28 Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) announced today that it ... March,6, 2008, before the U.S. financial markets open. Management will provide a,Company ... 6, 2008, at 9:00 a.m. EST., Investors and ... ...
... New England Journal of Medicine, led by researchers at ... University of Massachusetts Medical School (UMMS), indicates a declining ... the first demonstration of a link between two independent ... has offered universal newborn screening to detect cystic fibrosis ...
Cached Biology Technology:Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008 2Data show a decline in cystic fibrosis since introduction of prenatal carrier screening 2
(Date:9/19/2014)... resource unveiled today by researchers from several Harvard ... provides both experienced and aspiring researchers with the ... operate robots made from soft, flexible materials. , ... cutters, and other advances in manufacturing technology, soft ... Using principles drawn from conventional rigid robot design, ...
(Date:9/19/2014)... of Oklahoma biology professor will study multifunctional and ... movements with a National Science Foundation grant in ... , Ari Berkowitz, professor in the Department of ... focus on the differences between the multifunctional and ... neurotransmitters they use and what connections they make. ...
(Date:9/19/2014)... Imagine you are a species which over thousands of years ... exposed to a substance that makes the cold dangerous for ... Enchytraeus albidus , and the cold provoking substance, called ... cosmetics. , Nonylphenol is suspected of being a endocrine disruptor, ... It inhibits the worm,s ability to protect the cells in ...
Breaking Biology News(10 mins):Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... This press release is available in ... scientists working with the University of Illinois at Urbana-Champaign ... soybean yields by an average 23 percent. Randy ... Research Service Soybean/Maize Germplasm, Pathology, and Genetics Research Unit ...
... DC, Aug. 22The Martin Luther King, Jr. Health Equity ... Multicultural and Minority Medicine (IAMMM), opens today as the ... opens to the public on the National Mall. Both ... focusing tightly on the health status of minorities and ...
... a five-year grant is considered a long-term grant, Alan R. Templeton, ... University in St. Louis, has managed to follow some of the ... Early in his career he studied parthenogenesis, or virgin birth, in ... Hawaii. "Drosophilia have fast generation times," he says, "but I ...
Cached Biology News:Breeding ozone-tolerant crops 2MLK, Jr. Health Equity Summit opens as memorial to Dr. King is unveiled in DC 2Restoration as science: case of the collared lizard 2Restoration as science: case of the collared lizard 3Restoration as science: case of the collared lizard 4Restoration as science: case of the collared lizard 5Restoration as science: case of the collared lizard 6Restoration as science: case of the collared lizard 7Restoration as science: case of the collared lizard 8Restoration as science: case of the collared lizard 9
Purified anti-LAT...
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Request Info...
Biology Products: